Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rHSA/IFNα2a in Chronic Hepatitis B
NCT01997944Phase 2Completed
- Sponsor
- Beijing Bio-Fortune Ltd.
- Start
- Nov 2013
- Primary completion
- Sep 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of albinterferon alfa-2a in hepatitis B (HBV), sponsored by Beijing Bio-Fortune Ltd.. Started Nov 2013; status: completed.
02
Drugs
albinterferon alfa-2a
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT01997944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01997944.